Anika Therapeutics, Inc. (ANIK) Earnings History
Annual and quarterly earnings data from 1993 to 2025
Loading earnings history...
ANIK EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ANIK Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 56.6% | -9.8% | -9.6% |
| 2024 | 63.4% | -4.3% | -47.0% |
| 2023 | 68.3% | 0.7% | -68.4% |
| 2022 | 64.3% | 3.2% | -13.1% |
| 2021 | 56.1% | 1.8% | 2.8% |
Download Data
Export ANIK earnings history in CSV or JSON format
Free sign-in required to download data
Anika Therapeutics, Inc. (ANIK) Earnings Overview
As of May 8, 2026, Anika Therapeutics, Inc. (ANIK) reported trailing twelve-month net income of -$11M, reflecting +80.2% year-over-year growth. The company earned $-0.82 per diluted share over the past four quarters, with a net profit margin of -9.6%.
Looking at the long-term picture, ANIK's historical earnings data spans multiple years. The company achieved its highest annual net income of $38M in fiscal 2014.
Anika Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MDXG ($31M net income, 11.6% margin), NVCR (-$173M net income, -20.8% margin), OSUR (-$53M net income, -59.8% margin), ANIK has room to improve margins relative to the peer group. Compare ANIK vs MDXG →
ANIK Earnings vs Peers
Earnings metrics vs comparable public companies
ANIK Historical Earnings Data (1993–2025)
33 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$11M | +80.7% | -$11M | $-0.76 | -9.6% | -9.8% |
| 2024 | -$56M | +31.8% | -$5M | $-3.83 | -47.0% | -4.3% |
| 2023 | -$83M | -456.3% | $844,000 | $-5.64 | -68.4% | 0.7% |
| 2022 | -$15M | -459.4% | $4M | $-1.02 | -13.1% | 3.2% |
| 2021 | $4M | +117.2% | $3M | $0.28 | 2.8% | 1.8% |
| 2020 | -$24M | -188.2% | -$28M | $-1.69 | -18.4% | -21.7% |
| 2019 | $27M | +45.2% | $34M | $1.89 | 23.7% | 29.9% |
| 2018 | $19M | -41.2% | $22M | $1.27 | 17.7% | 20.6% |
| 2017 | $32M | -2.2% | $46M | $2.11 | 28.1% | 40.3% |
| 2016 | $33M | +5.8% | $51M | $2.15 | 31.5% | 49.0% |
See ANIK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ANIK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ANIK vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonANIK — Frequently Asked Questions
Quick answers to the most common questions about buying ANIK stock.
Is ANIK growing earnings?
ANIK EPS is $-0.82, with earnings growth accelerating to +80.2%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-11M.
What are ANIK's profit margins?
Anika Therapeutics, Inc. net margin is -9.6%, with operating margin at -9.8%. Below-average margins reflect competitive or cost pressures.
How consistent are ANIK's earnings?
ANIK earnings data spans 1993-2025. The accelerating earnings trend is +80.2% YoY. Historical data enables comparison across business cycles.